Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Dana-Farber Cancer Institute
With
Yale University
Susan G. Komen Breast Cancer Foundation
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Newly diagnosed, histologically confirmed stage I-III breast cancer
Planning to undergo definitive surgical management with lumpectomy or mastectomy with in the next 8 weeks.
Willing and able to participate in the intervention for at least 3 weeks prior to surgery.
ECOG performance status of 0 or 1
Approval by oncologist or surgeon
Willingness to be randomized.
English speaking and able to read English
You may not be if
Concurrent other malignancy or history of other malignancy treated within the past 3 years (other than non-melanoma skin cancer or in situ cervical cancer)
Presence of metastatic disease
Scheduled to receive any form of neoadjuvant cancer therapy
Locally advanced breast cancer not amenable to primary surgery
History of prior ipsilateral breast cancer
Taking tamoxifen, raloxifene or an aromatase inhibitor at the time of breast cancer diagnosis
Absolute contraindications to maximal exercise testing as recommended by the American Thoracic Society
Any condition which in the investigator's opinion makes the subject unsuitable for study participation
Participating in another clinical study with competing study outcomes
Pregnant (i.e., positive beta-HCG) or breast feeding
Unable to comply with protocol and/or not available for follow-up assessments
Participation in more than 90 minutes a week of moderate-intensity recreational activity (not including activities such as gardening, bowling, golfing with a cart) as assessed by the Leisure Score Index of Godin Leisure- Time Exercise Questionnaire (LSI) (Appendix I) or recent participation (past 6 months) in two or more strength training sessions per week.
Diabetes mellitus requiring insulin or oral agents; patients with diet-controlled diabetes will be allowed to participate
